Targeting mTOR in renal cell carcinoma

The mammalian target of rapamycin (mTOR) is clearly an important therapeutic target for advanced renal cell carcinoma (RCC), although its mechanisms of activation are not completely understood. In first‐line treatment of patients who have both advanced RCC and multiple risk factors for short surviva...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer 2009-05, Vol.115 (S10), p.2313-2320
1. Verfasser:	Hudes, Gary R.
Format:	Artikel
Sprache:	eng
Schlagworte:	Akt Antineoplastic Combined Chemotherapy Protocols Biological and medical sciences Carcinoma, Renal Cell - drug therapy Clinical Trials as Topic Drug Delivery Systems Drug Resistance, Neoplasm Everolimus Humans Interferons Kidney Neoplasms - drug therapy Kidneys Medical sciences mTOR Nephrology. Urinary tract diseases PI3K Protein Kinases - physiology renal cell carcinoma Signal Transduction Sirolimus - administration & dosage Sirolimus - analogs & derivatives Sirolimus - therapeutic use targeted therapy TOR Serine-Threonine Kinases Tumors Tumors of the urinary system
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!